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Abstract
Apolipoprotein(a) [apo(a)] is an apolipoprotein unique to lipoprotein(a) [Lp(a)]. Although it has
no known function, Lp(a) is a risk factor for accelerated atherothrombosis. We hypothesize that
LPA, the gene which encodes apo(a), is a heretofore unrecognized unprocessed pseudogene
created by duplication of PLG, the gene which encodes plasminogen. Unprocessed pseudogenes
are genes which were created by duplication of functional genes and subsequently lost function
after acquiring various mutations. This hypothesis explains many of the unusual features of
Lp(a) and apo(a). Also, this hypothesis has implications for the therapy of elevated Lp(a) and
atherothrombosis theory. Because apo(a) is functionless, the diseases associated with elevated
levels of Lp(a) are due to its impact on blood viscosity.
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Keywords: atherothrombosis, apolipoprotein(a), lipoprotein a, pseudogene, blood viscosity
Introduction And Background
Lipoprotein(a) and apolipoprotein(a)
Lipoprotein(a) [Lp(a)] is a particle composed of a core which is indistinguishable from that of
low density lipoprotein (LDL) and a single molecule of apolipoprotein(a) [apo(a)]. Lp(a) is
clinically significant because it is a risk factor for accelerated atherothrombosis as well as
arterial and venous thrombosis. Lp(a) and apo(a) have several unusual features. After decades
of study, no physiologic function has been definitively attributed to either. Plasma
concentrations of Lp(a) vary by three orders of magnitude, from undetectable to > 200 mg/dl
[1]. This degree of variation is very unusual for an analyte present in mg/dl concentrations. The
extreme variation in molecular weight of apo(a) is unique [2]. This is due to variation in the
number of kringle IV-like domains in the protein. These domains are important in protein-
protein interactions, and are present in several different proteins, including plasminogen. The
similarities between apo(a) and plasminogen are widely-recognized. Apo(a) possesses between
15 to 43 copies of this domain [1]. This variation reflects differences in LPA, the gene which
encodes apo(a). There are at least 34 alleles of this gene, including a null allele which does not
produce protein. Because these alleles are present in roughly similar frequencies,
heterozygosity (the percentage of individuals who are heterozygous at a particular locus) for
LPA is extraordinarily high. In a study of multiple populations, the average heterozygosity at
the LPA locus was 94%, the highest reported up to that time [3].
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Pseudogenes
Pseudogenes have been defined as copies of protein-encoding genes that are thought to no
longer have the same functional product as their parental gene but still share significant
sequence similarity [4]. LPA has significant homology to PLG, the gene which encodes
plasminogen, but has a 27 nucleotide deletion in the protease domain, among several other
differences [vide infra]. Thus, apo(a) can be considered a defective form of plasminogen which
qualifies LPA as a pseudogene. In humans, it is estimated that there are approximately 16,881
pseudogenes, compared to 20,687 genes which encode functional proteins. Approximately 168
pseudogenes express peptides or proteins [5].
Three types of pseudogenes are recognized: processed, unprocessed, and unitary. Processed
pseudogenes are created when complementary DNA (cDNA) is synthesized from mRNA and
then inserted into a DNA strand. Because a promoter is not present in cDNA, processed
pseudogenes are functionless. It is estimated that humans have approximately 8,000 processed
pseudogenes [6]. 
Unprocessed pseudogenes are created by unequal recombination during crossover in meiosis
(Figure 1).
FIGURE 1: Generation of an unprocessed pseudogene by
unequal recombination of homologous genes due to
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misalignment
In LPA, the gene which encodes apolipoprotein(a), two Alu elements, the most common type of
SINE (short interspersed nuclear element), are present in the untranslated 5' region. (Modified
from original artwork by Dennis Pietras. From Wikimedia Commons.)
This occurs when misalignment of homologous genes causes one chromosome to have two
copies of the gene and the other none following DNA replication. Misalignment happens when
two DNA strands bind at the wrong conserved repetitive sequence. Conserved repetitive
sequences such as SINEs (short interspersed nuclear elements) are DNA sequences which are
repeated multiple times throughout the genome. The most common SINEs are Alu elements, a
family of DNA sequences approximately 300 base pairs long which are repeated over one
million times and comprise approximately 10% of the human genome [7].
The high prevalence of conserved repetitive sequences explains why duplicate genes arise at a
“very high” rate, an average of 0.01 per gene per million years. Because duplicate genes are
generally assumed to be functionally redundant, their likeliest evolutionary outcome is to
accumulate mutations, creating a pseudogene. Alternatively, duplicate genes may persist in an
effectively neutral or beneficial manner [8]. Both outcomes are seen in the alpha-like globin
cluster on chromosome 16 and the beta-like globin cluster on chromosome 11. Both clusters
were formed by multiple duplication events. The alpha globin cluster consists of five functional
genes and two unprocessed pseudogenes, HBAP1 and HBZP1. The beta globin cluster consists
of five coding genes and one unprocessed pseudogene, HBBP1. The functional genes in both
clusters are sequentially expressed in development in the order they evolved, resulting in
distinct hemoglobins during the embryonic, fetal, and adult stages, an example of ontogeny
recapitulating phylogeny.
Recently, functionality has been attributed to some genes classified as pseudogenes. The best
documented example is said to be XIST, or X inactive specific transcript, which has sequence
homology to a chicken gene called LNX3 [9]. XIST is transcribed but not translated. It encodes
an RNA which silences transcription of many genes on one X chromosome in females, an
example of a long noncoding RNA (lncRNA) modifying gene expression. The crux of the
argument that XIST is a pseudogene is that the gene does not express protein and is
surrounded by pseudogenes [10]. A mutation which prevents a gene from being normally
expressed creates a unitary pseudogene. XIST is surrounded by two unrelated processed
pseudogenes, FXYD6P3, which is one of three pseudogenes derived from the gene which
encodes FXYD domain-containing ion transport regulator 6, a sodium transport channel
regulator, and SEPHS1P4, one of four pseudogenes derived from the gene encoding
selenophosphate synthetase 1.
Instead of “pseudogenization,” Elisaphenko et al. demonstrated that XIST arose de novo from
four exons from LNX3 and six exons consisting of short tandem repeats derived from
transposons [11]. It is the latter which are necessary for transcriptional silencing of the X
chromosome. A mutation in the start codon caused loss of protein expression before new exons
imparted function to XIST, creating a new gene. Thus, the crucial contribution of LNX3 was the
promoter region, which is among the most highly conserved regions of XIST, not the exons that
encode a protein which is obviously nonessential.
The process which produced XIST is the evolution of a unitary pseudogene into one with a
function. This is fundamentally different from the mutations which created the processed
pseudogenes which surround XIST, the unprocessed pseudogenes in the alpha and beta globin
clusters, or the unitary pseudogene precursor to XIST. It is debatable if the mere presence of a
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nucleotide sequence which is homologous to one in a gene which produces a protein
constitutes a pseudogene because expression of a protein is not necessary for a gene to be
functional. XIST is an example of a gene whose function is mediated by lncRNA, not a protein.
The presence of processed pseudogenes adjacent to XIST may simply be a consequence of their
prevalence.
It has been suggested that antisense transcription can impart functionality to a
pseudogene. Transcription of both strands of DNA, a process known as convergent
transcription, is extremely unlikely because RNA polymerase II complexes cannot bypass each
other in vitro, and transcription ceases when they collide [12]. It has also been suggested that
mRNA encoded by a “pseudogene” could be functional by binding to microRNA and preventing
it from silencing other mRNAs. If such a gene is present in germline DNA, it can be argued that
it is a product of evolution, and the gene is not a pseudogene. The label “pseudogene” was
originally applied to genes which were thought to be nonfunctional. To apply this term to genes
which have a function is misleading and distorts the meaning of a useful term.
Review
The authors hypothesize that LPA is a heretofore unrecognized unprocessed pseudogene. LPA
arose in a primate ancestor from duplication of PLG, the gene which encodes plasminogen. The
5’ untranslated regions of LPA and PLG are nearly identical, and contain two Alu elements [13].
After this duplication event, the gene subsequently underwent deletions of kringles I-III as well
as deletions in the sequences encoding the protease domain and preactivation peptide. Also,
kringle IV was duplicated a highly variable number of times. Because of these mutations, apo(a)
has no fibrinolytic activity [1].
Gene sequences with function tend to be evolutionarily conserved while nonfunctional
sequences diverge because of the accumulation of duplications, deletions and other mutations
[14]. The accumulation of mutations and large variation in the number of kringle IV sequences
strongly suggests that LPA is a nonfunctional gene. It would be surprising if a gene with so
many common alleles expressed a protein with a necessary function. Not surprisingly, humans
with loss of function mutations at the LPA locus are healthy [15].
The apo(a)-plasminogen gene cluster
LPA is surrounded by unprocessed pseudogenes (Figure 2).
FIGURE 2: Chromosome 6q25.3-6q26
The genes LPAL2 (lipoprotein(a)-like 2), an unprocessed pseudogene, LPA, and PLG, the gene
encoding plasminogen, are clustered in this region. Pseudogenes are present on both sides of
LPA (large arrows). A long intergenic noncoding RNA (lincRNA) is indicated by the small arrow.
(Courtesy of Ensembl 92. http://uswest.ensembl.org/Homo_sapiens/Location/Overview?
db=core;g=ENSG00000198670;r=6:160237877-160957878)
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One, named LPAL2, is homologous to LPA, but all transcripts are truncated and eliminated by
nonsense-mediated decay, a surveillance pathway which eliminates mRNAs that have
premature stop codons. The second pseudogene is designated AL109933.2. This gene contains a
plasminogen tail-like sequence with a frameshift mutation resulting in a stop codon. A
second mutation which destroys a consensus splicing site is found in a large intron separating
the exon coding for the leader from the one encoding the tail-like sequences [16].
Finally, a long intergenic noncoding RNA (lincRNA) is present between AL109933.2 and PLG.
Thus, PLG has undergone at least three separate duplications, creating three unprocessed
pseudogenes. PLG, LPA, LPAL2, AL109933.2, and the gene encoding the lincRNA comprise the
apo(a)-plasminogen gene cluster.
Lp(a) is a modified LDL
Lp(a) does not have a triacylglycerol-rich precursor, unlike LDL [17]. Instead, Lp(a) derives from
the disulfide linkage of apo(a) to apolipoprotein B-100 (apoB-100) of pre-existing LDL. ApoB-
100 undergoes conformational changes which uncover new epitopes in the transition from very
low density lipoprotein (VLDL) to LDL [18]. Because apoB-100 forms a belt around the lipid core
of a particle, the decrease in circumference accompanying the transition from VLDL to LDL may
expose these new epitopes. Alternatively, loss of the other apolipoproteins in VLDL could
cause the conformational changes. These conformational changes could explain why apo(a)
binds to LDL and not VLDL. Koschinsky, et al. demonstrated that the disulfide linkage between
apoB-100 and apo(a) occurs extracellularly in a two-step process. First, a strong noncovalent
bond is formed between the two molecules, which is followed by the covalent disulfide linkage
[19].
Because Lp(a) is modified LDL, changes in the concentration of Lp(a) parallel changes in the
concentration of LDL. Sandholzer, et al. found that concentrations of both LDL and Lp(a) were
very low in subjects with lipoprotein lipase deficiency and Type III hyperlipidemia
[17]. Reductions of Lp(a) strongly correlated with reductions of LDL and apolipoprotein B in
trials of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [20]. Statin therapy
reduced levels of both LDL and Lp(a) in patients with heterozygous familial
hypercholesterolemia [21]. Drugs which increase the number of LDL receptors (LDLR) such as
statins and PCSK9 inhibitors are more effective in reducing LDL levels than Lp(a) levels because
Lp(a) competes poorly with LDL for binding to LDLR [22]. Additionally, Lp(a) levels are elevated
in subjects with familial hypercholesterolemia [23].
Implications for atherothrombosis theory and therapy
The true nature of LPA as a pseudogene may have escaped notice because the overwhelming
majority of pseudogenes do not express protein. Perhaps more importantly, uncertainty about
the pathogenesis of atherothrombosis made it impossible to eliminate an unrecognized
function for Lp(a) and apo(a). Even the most optimistic proponent of lipid or inflammatory
theory must recognize that those theories are inadequate to explain important phenomena
such as the protection afforded by premenopausal status or increased levels of high density
lipoprotein (HDL), or the circadian variation in atherothrombotic events. We have recently
reviewed the shortcomings of mainstream atherothrombosis theory [24]. 
Accumulation of Lp(a) in the arterial intima is thought to accelerate atherothrombosis, possibly
because of putative residual function of apo(a). Accumulation of Lp(a) (or LDL) in the arterial
wall cannot be the cause of accelerated atherothrombosis for several reasons. All plasma
macromolecules, including LDL and Lp(a), are present throughout the arterial intima in
concentrations directly related to their molecular weight and plasma concentration [25].
Macromolecular transport across the venous endothelium is even greater than across the
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arterial endothelium [26], and veins do not develop atherothrombosis. Therefore, the presence
of LDL or Lp(a) in the arterial intima cannot explain the characteristic localization of
atherosclerotic plaques to areas of low shear and changing arterial geometry. The
glycosaminoglycans, fibronectin, and collagen necessary to retain LDL or Lp(a) are present
throughout the arterial intima [25]. The quantity of these lipoprotein-binding molecules is
increased in diffuse intimal thickening, a universal change in the arteries of adults [25]. The
increased trapping of LDL and Lp(a) in atherosclerotic plaques is simply a consequence of the
great amount of collagen and proteoglycans in plaques. Type Vc atheroscleroic plaques have
little or no extra-celluar lipid, and consist of collagen and proteoglycans [27]. In the experience
of one author (GDS), this is the most common type of plaque, particularly since the widespread
use of statins. 
Further, a mechanism is present in the intima to eliminate plasma constituents which enter the
subendothelial space. This should not be surprising because their presence is
physiologic. Dendritic cells, a normal component of the intima, constitutively sample the
aqueous environment of the subendothelial space by macropinocytosis. Dendritic cells can
pinocytose 100x their volume per hour in vitro. Molecules which cannot be catabolized by
lysosomal enzymes such as cholesterol are packaged in exosomes which allows them to
circulate to the liver for catabolism. Dendritic cells assume the morphology of foam cells
because their great capacity for pinocytosis allows them to accumulate cholesterol faster than it
can be eliminated. The ability to eliminate cholesterol allows fatty streaks, the putative
precursor to the atherosclerotic plaque, to routinely resolve without pathologic sequelae [28].
We have reviewed this pathway in reference [29]. 
The notion that the accumulation of Lp(a), LDL, or cholesterol in the intima is atherogenic is an
example of the “fallacy of the simple explanation,” which states that the appeal of simplicity
causes acceptance of simplistic and incorrect explanations. The words of HL Mencken should
always be remembered: “For every complex problem, there is a solution that is simple, direct,
and wrong” [24].
Instead, we believe that the accelerated atherothrombosis associated with elevated Lp(a) (and
LDL) is due to increased blood viscosity in areas of low shear rate [29]. These develop in areas
of flow separation which occur naturally in areas of changing vascular geometry. In these areas,
Lp(a) and LDL foster progressive erythrocyte aggregation which increases blood
viscosity. Unremitting positive feedback may develop whereby increased blood viscosity allows
further erythrocyte aggregation, which further increases viscosity and slows flow, allowing
further aggregation, etc. Areas of sluggish blood flow are predisposed to thrombosis as noted by
the German pathologist Rudolph Virchow in the 19th century. Atherosclerotic plaques develop
from the organization of mural thrombi, as originally proposed by the Welsh pathologist John
Duguid in the mid-twentieth century [29]. 
The association of elevated Lp(a) with arterial thrombosis [30] and venous thromboembolism
[31] is more consistent with an effect on blood viscosity than putative pathologic effects caused
by its accumulation in a vessel wall. Venous thromboembolism associated with elevated levels
of Lp(a) has even been noted in children [32].
The most common risk factors for accelerated atherothrombosis are associated with increased
blood viscosity [29, 33-35]. Duguid’s thrombogenic hypothesis explains why diverse risk factors
produce the same lesion, the atherosclerotic plaque. It also provides insight into the protection
against atherothrombosis afforded by HDL, which decreases blood viscosity [36], the failure of
cholesteryl ester transfer protein inhibitors [37] and the excess cardiovascular mortality caused
by consumption of the Western diet and trans fats [38]. Our study of blood viscosity has also
provided insight into the cause of several anemias, including those associated with heart failure
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[39], chronic disease and inflammation, and hemolytic anemias [40].
Lipoprotein apheresis is the most effective therapy for reducing Lp(a) levels. Most methods
remove all apolipoprotein B-containing lipoproteins. This procedure has been shown to
decrease plasma viscosity [41-42]. In areas where therapeutic apheresis is not available,
therapeutic phlebotomy and blood donation are alternative means of lowering blood viscosity.
These interventions improve blood viscosity by replacing older, stiffer erythrocytes with fresh
deformable ones. Blood donation has two further advantages: it helps recipients of the
donation, and mobile blood collection vehicles can extend the therapy to underserved areas. A
high-risk population such as those with elevated plasma levels of Lp(a) without clinical disease
could be an ideal population for a prospective study of blood donation on atherothrombosis.
The fact that Lp(a) has no function suggests that oligonucleotide antisense therapy may be safe
if the oligonucleotide does not cross-react with other nucleotides.
The existence of Lp(a) is a consequence of a chance event, the mistake in homologous
recombination which created LPA. It did not result from an evolutionary development which
conferred a competitive advantage. The fact that apo(a) is the product of a pseudogene explains
many of the unusual properties of Lp(a). No function is to be expected in the product of a
pseudogene. The extreme heterogeneity in the size of apo(a) is due to the fact that there is no
constraint on the number of mutations a pseudogene can acquire. With the exception of a
premature stop codon, changes in a gene, such as the number of kringle sequences, will be
reflected in the protein encoded by that gene. The extreme variation in plasma concentrations
of Lp(a) at both ends of its range is also explained. Obviously, absence of a functionless particle
is not disadvantageous. The variability in the size of apo(a) also plays a role in determining
plasma concentrations because there is an inverse correlation between apo(a) size and plasma
concentration of Lp(a). The number of kringle IV repeats accounts for 69% of variance in
plasma concentrations of Lp(a). Overall, 91% of variance in plasma concentrations of Lp(a) is
determined genetically [43]. The fact that there is no constraint on the accumulation of
mutations also explains the extraordinary degree of heterozygosity in apo(a) genotype. Because
mutations in LPA have no impact on reproductive fitness, there is no selective pressure acting
to eliminate an allele from the gene pool. Boerwinkle et al. even observed the de novo
generation of a new allele during the course of their study, an event which occurred once in 376
meioses [43]. Presumably, expression of apo(a) is controlled by the same regulatory elements as
plasminogen. Plasma concentrations of plasminogen vary little or none over 24 hours [44]. This
explains why changes in lifestyle have little impact on plasma concentrations of Lp(a).
Conclusions
The insight that apo(a) is the product of a pseudogene clarifies much of the mystery
surrounding Lp(a): its lack of function, its remarkable variation in plasma concentration, and
why its absence is not associated with ill health. It explains the wide variation in the molecular
weight of apo(a) and the extreme heterogeneity at the LPA locus. These characteristics are
inconsistent with a functional entity under homeostatic control. This insight also clarifies the
role of Lp(a) in accelerated atherothrombosis. Lack of function is one reason why accumulation
of apo(a) in the arterial wall does not cause the accelerated atherothrombosis associated with
elevated levels of Lp(a). Rather, Lp(a) (and LDL) accelerate atherothrombosis by increasing
blood viscosity. The most effective intervention for elevated levels of Lp(a), therapeutic
apheresis, works by decreasing blood viscosity. In areas where this intervention is not available,
therapeutic phlebotomy or blood donation are alternatives.
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